These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2995 related items for PubMed ID: 30424892

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Cardiovascular Safety, Long-Term Noncardiovascular Safety, and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis With Trial Sequential Analysis.
    Zhang XL, Zhu QQ, Chen YH, Li XL, Chen F, Huang JA, Xu B.
    J Am Heart Assoc; 2018 Jan 20; 7(2):. PubMed ID: 29353233
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
    Heerspink HJL, Kosiborod M, Inzucchi SE, Cherney DZI.
    Kidney Int; 2018 Jul 20; 94(1):26-39. PubMed ID: 29735306
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Comparison the effects of finerenone and SGLT2i on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus: A network meta-analysis.
    Li X, Wu H, Peng H, Jiang H.
    Front Endocrinol (Lausanne); 2022 Jul 20; 13():1078686. PubMed ID: 36589800
    [Abstract] [Full Text] [Related]

  • 34. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.
    Neuen BL, Young T, Heerspink HJL, Neal B, Perkovic V, Billot L, Mahaffey KW, Charytan DM, Wheeler DC, Arnott C, Bompoint S, Levin A, Jardine MJ.
    Lancet Diabetes Endocrinol; 2019 Nov 20; 7(11):845-854. PubMed ID: 31495651
    [Abstract] [Full Text] [Related]

  • 35. SGLT2 inhibitors for prevention of primary and secondary cardiovascular outcomes: A meta-analysis of randomized controlled trials.
    He G, Yang G, Huang X, Luo D, Tang C, Zhang Z.
    Heart Lung; 2023 Nov 20; 59():109-116. PubMed ID: 36801545
    [Abstract] [Full Text] [Related]

  • 36. Cardiovascular and Renal Outcomes With Sodium-Glucose Cotransporter-2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors Combination Therapy: A Meta-Analysis of Randomized Cardiovascular Outcome Trials.
    Singh AK, Singh A, Singh R.
    Endocr Pract; 2023 Jul 20; 29(7):509-516. PubMed ID: 37037286
    [Abstract] [Full Text] [Related]

  • 37. Sodium-glucose Cotransporter-2 Inhibitors in Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Patients with Type 2 Diabetes Mellitus: A Meta-analysis.
    Kovil R, Chawla M, Shah T, Sahoo A, Makkar B, Kesavadev J, Seshadri K, Tiwaskar M, Rajput R, Phatak S, Majumdar S, Gupta S.
    J Assoc Physicians India; 2022 Aug 20; 70(8):11-12. PubMed ID: 36082726
    [Abstract] [Full Text] [Related]

  • 38. Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial.
    Schechter M, Wiviott SD, Raz I, Goodrich EL, Rozenberg A, Yanuv I, Murphy SA, Zelniker TA, Fredriksson M, Johansson PA, Leiter LA, Bhatt DL, McGuire DK, Wilding JPH, Gause-Nilsson IAM, Cahn A, Langkilde AM, Sabatine MS, Mosenzon O.
    Lancet Diabetes Endocrinol; 2023 Apr 20; 11(4):233-241. PubMed ID: 36878239
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. The renoprotective effects of sodium-glucose cotransporter 2 inhibitors versus placebo in patients with type 2 diabetes with or without prevalent kidney disease: A systematic review and meta-analysis.
    Wang C, Zhou Y, Kong Z, Wang X, Lv W, Geng Z, Wang Y.
    Diabetes Obes Metab; 2019 Apr 20; 21(4):1018-1026. PubMed ID: 30565382
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 150.